Nicolas H Phd Roelofs Net Worth

The estimated Net Worth of Nicolas H Phd Roelofs is at least $1.08 millió dollars as of 27 March 2013. Nicolas Roelofs owns over 53,443 units of Seer stock worth over $225,352 and over the last 17 years Nicolas sold SEER stock worth over $854,080.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nicolas Roelofs SEER stock SEC Form 4 insiders trading

Nicolas has made over 14 trades of the Seer stock since 2011, according to the Form 4 filled with the SEC. Most recently Nicolas exercised 53,443 units of SEER stock worth $1,574,431 on 27 March 2013.

The largest trade Nicolas's ever made was exercising 53,443 units of Seer stock on 27 March 2013 worth over $1,574,431. On average, Nicolas trades about 4,262 units every 24 days since 2007. As of 27 March 2013 Nicolas still owns at least 139,970 units of Seer stock.

You can see the complete history of Nicolas Roelofs stock trades at the bottom of the page.

Insiders trading at Seer

Over the last 7 years, insiders at Seer have traded over $150,878,393 worth of Seer stock and bought 1,798,420 units worth $33,507,980 . The most active insiders traders include Omid Farokhzad, Terrance Mcguire és Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of $227,813. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth $21,554.

What does Seer do?

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Complete history of Nicolas Roelofs stock trades at Agilent Technologies és Seer

Seer executives and stock owners

Seer executives and other stock owners filed with the SEC include:

• Dr. Omid C. Farokhzad M.D., Ph.D.,
  Founder, CEO & Chair of the Board of Directors
• Dr. Omid C. Farokhzad Ph.D., M.D.,
  CEO & Chair of the Board of Directors
• Omead Ostadan,
  Part Time Pres, COO & Director
• David R. Horn,
  Exec. VP & Chief Financial Officer
• Martin Goldberg Ph.D.,
  Sr. VP of Devel.
• Elona Kogan Esq., J.D.,
  Gen. Counsel & Sec.
• Marissa Dixon,
  VP & Chief People Officer
• Jennifer Maggio,
  VP & Corp. Controller
• Dr. Serafim Batzoglou,
  VP & Chief of Computation
• Shashanka Muppaneni,
  VP of Corp. Devel.
• Karen Possemato,
  VP of Corp. Marketing & Communications
• Elona Kogan J.D., Esq.,
  Gen. Counsel & Sec.
• Dr. Philip Ma Ph.D.,
  Founder & Strategic Advisor
• Joe Laws,
  Chief Technology Officer and Co-Founder
• David Hallal,
  
• Rachel E. Haurwitz,
  
• Dipchand Nishar,
  
• Mostafa Ronaghi,
  Director
• David B Singer,
  Director
• Public Equities, L.P.Invus ...,
  
• Omead Ostadan,
  President & COO
• David R. Horn,
  PRESIDENT & CFO
• Growth Fund Limited Partner...,
  
• Capital Ventures, Llc Maver...,
  
• Cathy Friedman,
  Director
• Terrance Mcguire,
  
• Capital Ventures, Llc Maver...,
  
• Robert Langer,
  
• Scott D Thomas,
  Chief Commercial Officer
• Public Equities, L.P.Artal ...,
  
• Meeta Gulyani,
  
• Omid Farokhzad,
  CEO AND CHAIR
• Elona Kogan,
  CHIEF LEGAL OFFICER
• Nicolas H Phd Roelofs,